Quarterly report pursuant to Section 13 or 15(d)

LICENSES ACQUIRED (Details)

v3.22.1
LICENSES ACQUIRED (Details)
$ in Thousands
3 Months Ended
Nov. 16, 2021
shares
Jun. 29, 2021
USD ($)
Mar. 31, 2022
USD ($)
item
Dec. 31, 2021
USD ($)
Licenses acquired        
Second installment payable     $ 6,285 $ 8,137
D F D Agreement        
Licenses acquired        
Amount payable   $ 10,000    
Amount payable to fund clinical trials       $ 24,000
D F D Agreement | Contingent Payment Derivative        
Licenses acquired        
Unregistered shares issued | shares 545,131      
Number of payments | item     1  
D F D Agreement | Minimum        
Licenses acquired        
Percentage of royalties payable on net sales   10.00%    
D F D Agreement | Maximum        
Licenses acquired        
Threshold additional contingent regulatory and commercial milestone payments payable   $ 163,000    
Percentage of royalties payable on net sales   20.00%